nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolutegravir—UGT1A1—Etoposide—testicular cancer	0.541	1	CbGbCtD
Dolutegravir—POU2F2—Ectoderm Differentiation—TFAP2C—testicular cancer	0.0244	0.524	CbGpPWpGaD
Dolutegravir—POU2F2—BCR signaling pathway—BCL10—testicular cancer	0.0161	0.346	CbGpPWpGaD
Dolutegravir—Rash macular—Ifosfamide—testicular cancer	0.0123	0.0321	CcSEcCtD
Dolutegravir—POU2F2—female gonad—testicular cancer	0.0122	0.395	CbGeAlD
Dolutegravir—Bilirubin total increased—Epirubicin—testicular cancer	0.0111	0.0291	CcSEcCtD
Dolutegravir—POU2F2—testis—testicular cancer	0.0108	0.351	CbGeAlD
Dolutegravir—Bilirubin total increased—Doxorubicin—testicular cancer	0.0103	0.0269	CcSEcCtD
Dolutegravir—Serum creatinine increased—Ifosfamide—testicular cancer	0.00818	0.0214	CcSEcCtD
Dolutegravir—POU2F2—lymph node—testicular cancer	0.00785	0.254	CbGeAlD
Dolutegravir—Serum creatinine increased—Cisplatin—testicular cancer	0.00705	0.0185	CcSEcCtD
Dolutegravir—Opportunistic infection—Methotrexate—testicular cancer	0.00591	0.0155	CcSEcCtD
Dolutegravir—Opportunistic infection—Epirubicin—testicular cancer	0.00553	0.0145	CcSEcCtD
Dolutegravir—Inflammation—Ifosfamide—testicular cancer	0.00519	0.0136	CcSEcCtD
Dolutegravir—Opportunistic infection—Doxorubicin—testicular cancer	0.00512	0.0134	CcSEcCtD
Dolutegravir—Myositis—Epirubicin—testicular cancer	0.00454	0.0119	CcSEcCtD
Dolutegravir—Neutropenia—Chlorambucil—testicular cancer	0.00446	0.0117	CcSEcCtD
Dolutegravir—Myositis—Doxorubicin—testicular cancer	0.0042	0.011	CcSEcCtD
Dolutegravir—Inflammation—Etoposide—testicular cancer	0.0041	0.0107	CcSEcCtD
Dolutegravir—Renal impairment—Ifosfamide—testicular cancer	0.00384	0.0101	CcSEcCtD
Dolutegravir—Serum creatinine increased—Epirubicin—testicular cancer	0.00362	0.00949	CcSEcCtD
Dolutegravir—Rash maculo-papular—Etoposide—testicular cancer	0.00361	0.00947	CcSEcCtD
Dolutegravir—Blood creatinine increased—Ifosfamide—testicular cancer	0.00342	0.00897	CcSEcCtD
Dolutegravir—Serum creatinine increased—Doxorubicin—testicular cancer	0.00335	0.00878	CcSEcCtD
Dolutegravir—Neutropenia—Dactinomycin—testicular cancer	0.00322	0.00844	CcSEcCtD
Dolutegravir—UGT1A1—NRF2 pathway—SLC2A6—testicular cancer	0.00308	0.0663	CbGpPWpGaD
Dolutegravir—Blood creatinine increased—Cisplatin—testicular cancer	0.00295	0.00773	CcSEcCtD
Dolutegravir—Hyperglycaemia—Ifosfamide—testicular cancer	0.00285	0.00746	CcSEcCtD
Dolutegravir—Renal failure—Ifosfamide—testicular cancer	0.00277	0.00725	CcSEcCtD
Dolutegravir—Hepatitis—Dactinomycin—testicular cancer	0.00276	0.00723	CcSEcCtD
Dolutegravir—Vertigo—Vinblastine—testicular cancer	0.00274	0.00718	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Ifosfamide—testicular cancer	0.00266	0.00698	CcSEcCtD
Dolutegravir—Abdominal discomfort—Cisplatin—testicular cancer	0.00261	0.00684	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Etoposide—testicular cancer	0.00255	0.00667	CcSEcCtD
Dolutegravir—Hepatitis—Ifosfamide—testicular cancer	0.00253	0.00662	CcSEcCtD
Dolutegravir—Urinary tract disorder—Ifosfamide—testicular cancer	0.0025	0.00654	CcSEcCtD
Dolutegravir—Urethral disorder—Ifosfamide—testicular cancer	0.00248	0.00649	CcSEcCtD
Dolutegravir—Inflammation—Methotrexate—testicular cancer	0.00245	0.00643	CcSEcCtD
Dolutegravir—Renal failure—Cisplatin—testicular cancer	0.00239	0.00625	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Epirubicin—testicular cancer	0.00236	0.00617	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Chlorambucil—testicular cancer	0.00234	0.00614	CcSEcCtD
Dolutegravir—Fatigue—Chlorambucil—testicular cancer	0.00234	0.00613	CcSEcCtD
Dolutegravir—Neutropenia—Etoposide—testicular cancer	0.00233	0.00611	CcSEcCtD
Dolutegravir—Inflammation—Epirubicin—testicular cancer	0.0023	0.00602	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Cisplatin—testicular cancer	0.0023	0.00602	CcSEcCtD
Dolutegravir—Immune system disorder—Ifosfamide—testicular cancer	0.00228	0.00598	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Chlorambucil—testicular cancer	0.00222	0.00582	CcSEcCtD
Dolutegravir—Mental disorder—Ifosfamide—testicular cancer	0.00221	0.0058	CcSEcCtD
Dolutegravir—Abnormal dreams—Epirubicin—testicular cancer	0.0022	0.00577	CcSEcCtD
Dolutegravir—Renal failure—Etoposide—testicular cancer	0.00219	0.00573	CcSEcCtD
Dolutegravir—Blood bilirubin increased—Doxorubicin—testicular cancer	0.00218	0.00571	CcSEcCtD
Dolutegravir—Urinary tract disorder—Cisplatin—testicular cancer	0.00215	0.00564	CcSEcCtD
Dolutegravir—Abdominal pain—Chlorambucil—testicular cancer	0.00215	0.00562	CcSEcCtD
Dolutegravir—Urethral disorder—Cisplatin—testicular cancer	0.00214	0.0056	CcSEcCtD
Dolutegravir—Inflammation—Doxorubicin—testicular cancer	0.00213	0.00557	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Etoposide—testicular cancer	0.0021	0.00551	CcSEcCtD
Dolutegravir—Abnormal dreams—Doxorubicin—testicular cancer	0.00204	0.00534	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Vinblastine—testicular cancer	0.00203	0.00533	CcSEcCtD
Dolutegravir—Rash maculo-papular—Epirubicin—testicular cancer	0.00203	0.00531	CcSEcCtD
Dolutegravir—Hypersensitivity—Chlorambucil—testicular cancer	0.002	0.00524	CcSEcCtD
Dolutegravir—Vertigo—Ifosfamide—testicular cancer	0.00198	0.00518	CcSEcCtD
Dolutegravir—Urinary tract disorder—Etoposide—testicular cancer	0.00197	0.00517	CcSEcCtD
Dolutegravir—Immune system disorder—Cisplatin—testicular cancer	0.00197	0.00516	CcSEcCtD
Dolutegravir—Abdominal pain—Vinblastine—testicular cancer	0.00197	0.00515	CcSEcCtD
Dolutegravir—Urethral disorder—Etoposide—testicular cancer	0.00196	0.00513	CcSEcCtD
Dolutegravir—Asthenia—Chlorambucil—testicular cancer	0.00195	0.0051	CcSEcCtD
Dolutegravir—Pruritus—Chlorambucil—testicular cancer	0.00192	0.00503	CcSEcCtD
Dolutegravir—Rash maculo-papular—Doxorubicin—testicular cancer	0.00187	0.00491	CcSEcCtD
Dolutegravir—Flatulence—Cisplatin—testicular cancer	0.00187	0.0049	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Ifosfamide—testicular cancer	0.00186	0.00487	CcSEcCtD
Dolutegravir—Diarrhoea—Chlorambucil—testicular cancer	0.00186	0.00487	CcSEcCtD
Dolutegravir—Hypersensitivity—Vinblastine—testicular cancer	0.00183	0.0048	CcSEcCtD
Dolutegravir—Immune system disorder—Etoposide—testicular cancer	0.0018	0.00473	CcSEcCtD
Dolutegravir—Asthenia—Vinblastine—testicular cancer	0.00178	0.00468	CcSEcCtD
Dolutegravir—Nervous system disorder—Ifosfamide—testicular cancer	0.00176	0.00461	CcSEcCtD
Dolutegravir—Skin disorder—Ifosfamide—testicular cancer	0.00174	0.00457	CcSEcCtD
Dolutegravir—Vomiting—Chlorambucil—testicular cancer	0.00173	0.00452	CcSEcCtD
Dolutegravir—Diarrhoea—Vinblastine—testicular cancer	0.0017	0.00446	CcSEcCtD
Dolutegravir—Renal impairment—Epirubicin—testicular cancer	0.0017	0.00445	CcSEcCtD
Dolutegravir—Fatigue—Dactinomycin—testicular cancer	0.00169	0.00443	CcSEcCtD
Dolutegravir—UGT1A1—Phase II conjugation—HPGDS—testicular cancer	0.00167	0.0361	CbGpPWpGaD
Dolutegravir—Dizziness—Vinblastine—testicular cancer	0.00165	0.00431	CcSEcCtD
Dolutegravir—Nausea—Chlorambucil—testicular cancer	0.00161	0.00423	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—testicular cancer	0.0016	0.0042	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Dactinomycin—testicular cancer	0.0016	0.0042	CcSEcCtD
Dolutegravir—Vomiting—Vinblastine—testicular cancer	0.00158	0.00414	CcSEcCtD
Dolutegravir—Renal impairment—Doxorubicin—testicular cancer	0.00157	0.00412	CcSEcCtD
Dolutegravir—Vertigo—Etoposide—testicular cancer	0.00156	0.00409	CcSEcCtD
Dolutegravir—Headache—Vinblastine—testicular cancer	0.00156	0.00408	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Ifosfamide—testicular cancer	0.00155	0.00406	CcSEcCtD
Dolutegravir—Abdominal pain—Dactinomycin—testicular cancer	0.00155	0.00406	CcSEcCtD
Dolutegravir—Fatigue—Ifosfamide—testicular cancer	0.00155	0.00406	CcSEcCtD
Dolutegravir—Hypersensitivity—Bleomycin—testicular cancer	0.00155	0.00406	CcSEcCtD
Dolutegravir—Nervous system disorder—Cisplatin—testicular cancer	0.00152	0.00398	CcSEcCtD
Dolutegravir—Blood creatinine increased—Epirubicin—testicular cancer	0.00152	0.00397	CcSEcCtD
Dolutegravir—Asthenia—Bleomycin—testicular cancer	0.00151	0.00395	CcSEcCtD
Dolutegravir—Skin disorder—Cisplatin—testicular cancer	0.0015	0.00394	CcSEcCtD
Dolutegravir—Pruritus—Bleomycin—testicular cancer	0.00149	0.0039	CcSEcCtD
Dolutegravir—Nausea—Vinblastine—testicular cancer	0.00148	0.00387	CcSEcCtD
Dolutegravir—Abdominal pain upper—Epirubicin—testicular cancer	0.00148	0.00387	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	0.00147	0.00385	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Ifosfamide—testicular cancer	0.00147	0.00385	CcSEcCtD
Dolutegravir—Hypersensitivity—Dactinomycin—testicular cancer	0.00144	0.00378	CcSEcCtD
Dolutegravir—Abdominal discomfort—Methotrexate—testicular cancer	0.00143	0.00375	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Epirubicin—testicular cancer	0.00143	0.00374	CcSEcCtD
Dolutegravir—Abdominal pain—Ifosfamide—testicular cancer	0.00142	0.00372	CcSEcCtD
Dolutegravir—Asthenia—Dactinomycin—testicular cancer	0.00141	0.00368	CcSEcCtD
Dolutegravir—Blood creatinine increased—Doxorubicin—testicular cancer	0.0014	0.00367	CcSEcCtD
Dolutegravir—Neutropenia—Methotrexate—testicular cancer	0.0014	0.00366	CcSEcCtD
Dolutegravir—Skin disorder—Etoposide—testicular cancer	0.00138	0.00361	CcSEcCtD
Dolutegravir—Abdominal pain upper—Doxorubicin—testicular cancer	0.00137	0.00358	CcSEcCtD
Dolutegravir—Diarrhoea—Dactinomycin—testicular cancer	0.00134	0.00351	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Cisplatin—testicular cancer	0.00134	0.0035	CcSEcCtD
Dolutegravir—Vomiting—Bleomycin—testicular cancer	0.00134	0.0035	CcSEcCtD
Dolutegravir—Rash—Bleomycin—testicular cancer	0.00132	0.00347	CcSEcCtD
Dolutegravir—Dermatitis—Bleomycin—testicular cancer	0.00132	0.00347	CcSEcCtD
Dolutegravir—Hypersensitivity—Ifosfamide—testicular cancer	0.00132	0.00347	CcSEcCtD
Dolutegravir—Alanine aminotransferase increased—Doxorubicin—testicular cancer	0.00132	0.00346	CcSEcCtD
Dolutegravir—Renal failure—Methotrexate—testicular cancer	0.00131	0.00343	CcSEcCtD
Dolutegravir—Neutropenia—Epirubicin—testicular cancer	0.00131	0.00343	CcSEcCtD
Dolutegravir—Asthenia—Ifosfamide—testicular cancer	0.00129	0.00338	CcSEcCtD
Dolutegravir—Pruritus—Ifosfamide—testicular cancer	0.00127	0.00333	CcSEcCtD
Dolutegravir—Hyperglycaemia—Epirubicin—testicular cancer	0.00126	0.0033	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Methotrexate—testicular cancer	0.00126	0.0033	CcSEcCtD
Dolutegravir—Nausea—Bleomycin—testicular cancer	0.00125	0.00327	CcSEcCtD
Dolutegravir—Vomiting—Dactinomycin—testicular cancer	0.00125	0.00326	CcSEcCtD
Dolutegravir—Rash—Dactinomycin—testicular cancer	0.00124	0.00324	CcSEcCtD
Dolutegravir—Diarrhoea—Ifosfamide—testicular cancer	0.00123	0.00322	CcSEcCtD
Dolutegravir—Renal failure—Epirubicin—testicular cancer	0.00123	0.00321	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Etoposide—testicular cancer	0.00122	0.00321	CcSEcCtD
Dolutegravir—Fatigue—Etoposide—testicular cancer	0.00122	0.0032	CcSEcCtD
Dolutegravir—Neutropenia—Doxorubicin—testicular cancer	0.00121	0.00317	CcSEcCtD
Dolutegravir—Hepatitis—Methotrexate—testicular cancer	0.0012	0.00313	CcSEcCtD
Dolutegravir—Dizziness—Ifosfamide—testicular cancer	0.00119	0.00311	CcSEcCtD
Dolutegravir—Urinary tract disorder—Methotrexate—testicular cancer	0.00118	0.00309	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Epirubicin—testicular cancer	0.00118	0.00309	CcSEcCtD
Dolutegravir—Urethral disorder—Methotrexate—testicular cancer	0.00117	0.00307	CcSEcCtD
Dolutegravir—Hyperglycaemia—Doxorubicin—testicular cancer	0.00117	0.00306	CcSEcCtD
Dolutegravir—Nausea—Dactinomycin—testicular cancer	0.00116	0.00305	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Etoposide—testicular cancer	0.00116	0.00304	CcSEcCtD
Dolutegravir—Vomiting—Ifosfamide—testicular cancer	0.00114	0.00299	CcSEcCtD
Dolutegravir—Hypersensitivity—Cisplatin—testicular cancer	0.00114	0.00299	CcSEcCtD
Dolutegravir—Renal failure—Doxorubicin—testicular cancer	0.00113	0.00297	CcSEcCtD
Dolutegravir—Rash—Ifosfamide—testicular cancer	0.00113	0.00297	CcSEcCtD
Dolutegravir—Dermatitis—Ifosfamide—testicular cancer	0.00113	0.00296	CcSEcCtD
Dolutegravir—Abdominal pain—Etoposide—testicular cancer	0.00112	0.00294	CcSEcCtD
Dolutegravir—Hepatitis—Epirubicin—testicular cancer	0.00112	0.00293	CcSEcCtD
Dolutegravir—Asthenia—Cisplatin—testicular cancer	0.00111	0.00291	CcSEcCtD
Dolutegravir—Urinary tract disorder—Epirubicin—testicular cancer	0.00111	0.0029	CcSEcCtD
Dolutegravir—Urethral disorder—Epirubicin—testicular cancer	0.0011	0.00287	CcSEcCtD
Dolutegravir—Hepatobiliary disease—Doxorubicin—testicular cancer	0.00109	0.00286	CcSEcCtD
Dolutegravir—Immune system disorder—Methotrexate—testicular cancer	0.00108	0.00283	CcSEcCtD
Dolutegravir—Nausea—Ifosfamide—testicular cancer	0.00107	0.0028	CcSEcCtD
Dolutegravir—Diarrhoea—Cisplatin—testicular cancer	0.00106	0.00278	CcSEcCtD
Dolutegravir—Mental disorder—Methotrexate—testicular cancer	0.00105	0.00275	CcSEcCtD
Dolutegravir—Hypersensitivity—Etoposide—testicular cancer	0.00104	0.00274	CcSEcCtD
Dolutegravir—Hepatitis—Doxorubicin—testicular cancer	0.00104	0.00271	CcSEcCtD
Dolutegravir—Urinary tract disorder—Doxorubicin—testicular cancer	0.00102	0.00268	CcSEcCtD
Dolutegravir—Asthenia—Etoposide—testicular cancer	0.00102	0.00267	CcSEcCtD
Dolutegravir—Urethral disorder—Doxorubicin—testicular cancer	0.00101	0.00266	CcSEcCtD
Dolutegravir—Immune system disorder—Epirubicin—testicular cancer	0.00101	0.00265	CcSEcCtD
Dolutegravir—Pruritus—Etoposide—testicular cancer	0.001	0.00263	CcSEcCtD
Dolutegravir—Vomiting—Cisplatin—testicular cancer	0.000984	0.00258	CcSEcCtD
Dolutegravir—Mental disorder—Epirubicin—testicular cancer	0.00098	0.00257	CcSEcCtD
Dolutegravir—UGT1A1—Biological oxidations—HPGDS—testicular cancer	0.000979	0.0211	CbGpPWpGaD
Dolutegravir—Rash—Cisplatin—testicular cancer	0.000976	0.00256	CcSEcCtD
Dolutegravir—Dermatitis—Cisplatin—testicular cancer	0.000975	0.00256	CcSEcCtD
Dolutegravir—Diarrhoea—Etoposide—testicular cancer	0.00097	0.00254	CcSEcCtD
Dolutegravir—Flatulence—Epirubicin—testicular cancer	0.00096	0.00252	CcSEcCtD
Dolutegravir—Dizziness—Etoposide—testicular cancer	0.000938	0.00246	CcSEcCtD
Dolutegravir—Immune system disorder—Doxorubicin—testicular cancer	0.000935	0.00245	CcSEcCtD
Dolutegravir—Vertigo—Methotrexate—testicular cancer	0.000935	0.00245	CcSEcCtD
Dolutegravir—Nausea—Cisplatin—testicular cancer	0.00092	0.00241	CcSEcCtD
Dolutegravir—Mental disorder—Doxorubicin—testicular cancer	0.000907	0.00238	CcSEcCtD
Dolutegravir—Vomiting—Etoposide—testicular cancer	0.000902	0.00236	CcSEcCtD
Dolutegravir—Rash—Etoposide—testicular cancer	0.000894	0.00234	CcSEcCtD
Dolutegravir—Dermatitis—Etoposide—testicular cancer	0.000893	0.00234	CcSEcCtD
Dolutegravir—Headache—Etoposide—testicular cancer	0.000889	0.00233	CcSEcCtD
Dolutegravir—Flatulence—Doxorubicin—testicular cancer	0.000888	0.00233	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.00088	0.00231	CcSEcCtD
Dolutegravir—Vertigo—Epirubicin—testicular cancer	0.000875	0.00229	CcSEcCtD
Dolutegravir—Nausea—Etoposide—testicular cancer	0.000842	0.00221	CcSEcCtD
Dolutegravir—Nervous system disorder—Methotrexate—testicular cancer	0.000833	0.00218	CcSEcCtD
Dolutegravir—Skin disorder—Methotrexate—testicular cancer	0.000825	0.00216	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000824	0.00216	CcSEcCtD
Dolutegravir—Vertigo—Doxorubicin—testicular cancer	0.00081	0.00212	CcSEcCtD
Dolutegravir—Nervous system disorder—Epirubicin—testicular cancer	0.00078	0.00204	CcSEcCtD
Dolutegravir—Skin disorder—Epirubicin—testicular cancer	0.000772	0.00202	CcSEcCtD
Dolutegravir—Insomnia—Methotrexate—testicular cancer	0.000768	0.00201	CcSEcCtD
Dolutegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000762	0.002	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000733	0.00192	CcSEcCtD
Dolutegravir—Fatigue—Methotrexate—testicular cancer	0.000732	0.00192	CcSEcCtD
Dolutegravir—Nervous system disorder—Doxorubicin—testicular cancer	0.000721	0.00189	CcSEcCtD
Dolutegravir—Insomnia—Epirubicin—testicular cancer	0.000719	0.00188	CcSEcCtD
Dolutegravir—Skin disorder—Doxorubicin—testicular cancer	0.000715	0.00187	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Methotrexate—testicular cancer	0.000695	0.00182	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000686	0.0018	CcSEcCtD
Dolutegravir—Fatigue—Epirubicin—testicular cancer	0.000685	0.0018	CcSEcCtD
Dolutegravir—Abdominal pain—Methotrexate—testicular cancer	0.000672	0.00176	CcSEcCtD
Dolutegravir—Insomnia—Doxorubicin—testicular cancer	0.000665	0.00174	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Epirubicin—testicular cancer	0.00065	0.0017	CcSEcCtD
Dolutegravir—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000635	0.00166	CcSEcCtD
Dolutegravir—Fatigue—Doxorubicin—testicular cancer	0.000634	0.00166	CcSEcCtD
Dolutegravir—Abdominal pain—Epirubicin—testicular cancer	0.000628	0.00165	CcSEcCtD
Dolutegravir—Hypersensitivity—Methotrexate—testicular cancer	0.000626	0.00164	CcSEcCtD
Dolutegravir—Asthenia—Methotrexate—testicular cancer	0.00061	0.0016	CcSEcCtD
Dolutegravir—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000602	0.00158	CcSEcCtD
Dolutegravir—Pruritus—Methotrexate—testicular cancer	0.000601	0.00157	CcSEcCtD
Dolutegravir—Hypersensitivity—Epirubicin—testicular cancer	0.000586	0.00153	CcSEcCtD
Dolutegravir—Abdominal pain—Doxorubicin—testicular cancer	0.000582	0.00152	CcSEcCtD
Dolutegravir—Diarrhoea—Methotrexate—testicular cancer	0.000581	0.00152	CcSEcCtD
Dolutegravir—Asthenia—Epirubicin—testicular cancer	0.00057	0.00149	CcSEcCtD
Dolutegravir—Pruritus—Epirubicin—testicular cancer	0.000562	0.00147	CcSEcCtD
Dolutegravir—Dizziness—Methotrexate—testicular cancer	0.000562	0.00147	CcSEcCtD
Dolutegravir—Diarrhoea—Epirubicin—testicular cancer	0.000544	0.00143	CcSEcCtD
Dolutegravir—Hypersensitivity—Doxorubicin—testicular cancer	0.000542	0.00142	CcSEcCtD
Dolutegravir—Vomiting—Methotrexate—testicular cancer	0.00054	0.00142	CcSEcCtD
Dolutegravir—Rash—Methotrexate—testicular cancer	0.000536	0.0014	CcSEcCtD
Dolutegravir—Dermatitis—Methotrexate—testicular cancer	0.000535	0.0014	CcSEcCtD
Dolutegravir—Headache—Methotrexate—testicular cancer	0.000532	0.00139	CcSEcCtD
Dolutegravir—Asthenia—Doxorubicin—testicular cancer	0.000528	0.00138	CcSEcCtD
Dolutegravir—Dizziness—Epirubicin—testicular cancer	0.000526	0.00138	CcSEcCtD
Dolutegravir—Pruritus—Doxorubicin—testicular cancer	0.00052	0.00136	CcSEcCtD
Dolutegravir—Vomiting—Epirubicin—testicular cancer	0.000505	0.00132	CcSEcCtD
Dolutegravir—Nausea—Methotrexate—testicular cancer	0.000505	0.00132	CcSEcCtD
Dolutegravir—Diarrhoea—Doxorubicin—testicular cancer	0.000503	0.00132	CcSEcCtD
Dolutegravir—Rash—Epirubicin—testicular cancer	0.000501	0.00131	CcSEcCtD
Dolutegravir—Dermatitis—Epirubicin—testicular cancer	0.000501	0.00131	CcSEcCtD
Dolutegravir—Headache—Epirubicin—testicular cancer	0.000498	0.00131	CcSEcCtD
Dolutegravir—Dizziness—Doxorubicin—testicular cancer	0.000486	0.00127	CcSEcCtD
Dolutegravir—Nausea—Epirubicin—testicular cancer	0.000472	0.00124	CcSEcCtD
Dolutegravir—Vomiting—Doxorubicin—testicular cancer	0.000468	0.00123	CcSEcCtD
Dolutegravir—Rash—Doxorubicin—testicular cancer	0.000464	0.00122	CcSEcCtD
Dolutegravir—Dermatitis—Doxorubicin—testicular cancer	0.000463	0.00121	CcSEcCtD
Dolutegravir—Headache—Doxorubicin—testicular cancer	0.000461	0.00121	CcSEcCtD
Dolutegravir—Nausea—Doxorubicin—testicular cancer	0.000437	0.00114	CcSEcCtD
Dolutegravir—UGT1A1—Metabolism—HPGDS—testicular cancer	0.000167	0.00361	CbGpPWpGaD
Dolutegravir—UGT1A1—Metabolism—STK11—testicular cancer	0.000122	0.00262	CbGpPWpGaD
